Description
BPA CANCELLATION
Base award description: BPA FOR RAVICTI, BUPHENYL, KRYSTEXXA, PROCYSBI, UPLIZNA
Modification chain · 5 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2024-09-04+$0= $0
- Mod P000012024-12-22+$0= $0
- Mod P000022025-04-28+$0= $0
- Mod P000032025-08-26+$0= $0
- Mod P000042025-10-29+$0= $0
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2024-09-04 | +$0 | $0 | BPA FOR RAVICTI, BUPHENYL, KRYSTEXXA, PROCYSBI, UPLIZNA |
| Mod P00001· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2024-12-22 | +$0 | $0 | 2025 PUBLIC LAW PRICING UPDATES |
| Mod P00002· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2025-04-28 | +$0 | $0 | DELETE KRYSTEXXA (NDC 75987-0080-10) AND UPLIZNA (NDC 75987-0150-03) |
| Mod P00003· EXERCISE AN OPTION | 2025-08-26 | +$0 | $0 | EXERCISE OPTION YEAR 1 |
| Mod P00004· LEGAL CONTRACT CANCELLATION | 2025-10-29 | +$0 | $0 | BPA CANCELLATION |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI SK1UK7S74GB3)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C24525N0427 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $76,897 | FY2025 |
| 36C24525N0296 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $76,897 | FY2025 |
| 36C24525N0224 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $37,269 | FY2025 |
| 36C24525N0145 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $37,269 | FY2025 |
| 36C24524N0929 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $55,903 | FY2024 |
| 36C24524N0914 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $55,903 | FY2024 |
Other recipients under 6505 from NAC PHARMACEUTICALS (36E797) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36E79726A0025 | CHIESI USA INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0024 | NEUROTECH PHARMACEUTICALS, INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0023 | TAKEDA PHARMACEUTICALS AMERICA, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726D0041 | GOLDEN STATE MEDICAL SUPPLY, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0022 | AURINIA PHARMA US INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_IDV_36E79724A0031_3600 · retrieved 2026-09-26.